Multiple sclerosis : clinical and laboratory research
-
Randomized Controlled Trial Multicenter Study
Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.
The Teriflunomide Multiple Sclerosis Oral (TEMSO) trial, a randomized, double-blind, placebo-controlled phase III study, demonstrated that teriflunomide significantly reduced annualized relapse rate (ARR), disease progression and magnetic resonance imaging (MRI) activity, with a favorable safety profile in relapsing multiple sclerosis (RMS) patients. ⋯ The positive effects of teriflunomide were demonstrated consistently across subgroups in TEMSO.
-
Randomized Controlled Trial
Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis.
Cognitive dysfunction occurs at the earliest stages of multiple sclerosis (MS), including the stage of clinically isolated syndrome (CIS). ⋯ To conclude, early IFNβ-1b treatment had a sustained positive effect on PASAT-3" score over the 5-year BENEFIT study.
-
Randomized Controlled Trial Multicenter Study
A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).
Open-label studies are not ideal for providing robust evidence for long-term maintenance of efficacy of medicines, especially where medicines provide symptom relief and where long-term use of a placebo may be problematic and not ethical. ⋯ Maintenance of Sativex efficacy in long-term symptomatic improvement of spasticity to a group of subjects with MS has been confirmed using this study design.
-
Randomized Controlled Trial Multicenter Study
Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
Health-related quality of life (HRQoL) worsens with multiple sclerosis (MS) relapses and disease progression. Common symptoms including depression and fatigue may contribute to poor HRQoL. ⋯ Fingolimod 1.25 mg may improve HRQoL and depression at 6 months compared with placebo in patients with relapsing MS.
-
Randomized Controlled Trial Multicenter Study
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Cladribine is a synthetic deoxyadenosine analogue in development as an oral multiple sclerosis (MS) therapy. ⋯ The safety and tolerability profile observed in the CLARITY study together with the reported efficacy support the potential for cladribine tablets as an MS therapy.